03:25 PM EST - Antibe Therapeutics Inc. : Announced that the first eight subjects have been enrolled and are on treatment in its key Phase 2B clinical trial, a double-blind, gastrointestinal (“GI”) safety study in 240 subjects with naproxen as a comparator. Naproxen is the most prescribed nonsteroidal anti-inflammatory drug in the USA. The study is designed to demonstrate the unequivocal superiority of ATB-346 in GI safety. Antibe Therapeutics Inc.
shares V.ATE are trading up $0.005 at $0.09.
